Evidence map›Paper›PMID 29159793›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2018

Curative radiation therapy for very elderly bladder cancer patients with localized disease.

M Bonet, T Bonfill, M Nuñez, L De Verdonces, E Mur, E Gallardo, L Fernandez-Morales, A Aguilar, J Prats, M Arenas

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

M BonetDepartment of Radiation Oncology, Hospital Universitari Sant Joan de Reus, Av. del Dr. Josep Laporte, 2, 43204, Reus, Tarragona, Spain. bonet.marta@gmail.com.ORCID http://orcid.org/0000-0002-6417-0514
T BonfillDepartment of Medical Oncology, Hospital Universitari Parc Taulí, Sabadell, Spain.
M NuñezDepartment of Radiation Oncology, Consorci Sanitari de Terrassa, Terrassa, Spain.
L De VerdoncesDepartment of Urology, Hospital Universitari Parc Taulí, Sabadell, Spain.
E MurDepartment of Radiation Oncology, Consorci Sanitari de Terrassa, Terrassa, Spain.
E GallardoDepartment of Medical Oncology, Hospital Universitari Parc Taulí, Sabadell, Spain.
L Fernandez-MoralesDepartment of Medical Oncology, Hospital Universitari Parc Taulí, Sabadell, Spain.
A AguilarDepartment of Urology, Consorci Sanitari de Terrassa, Terrassa, Spain.
J PratsDepartment of Urology, Hospital Universitari Parc Taulí, Sabadell, Spain.
M ArenasDepartment of Radiation Oncology, Hospital Universitari Sant Joan de Reus, Av. del Dr. Josep Laporte, 2, 43204, Reus, Tarragona, Spain.
Consorci Sanitari de Terrassa · ESDeleted InstitutionHospital Universitari Sant Joan de Reus · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo report the outcomes of a cohort of very elderly muscle-invasive bladder cancer (MIBC) patients treated with contemporary 3D-conformal radiation therapy (3D-CRT) with or without concurrent chemotherapy, after transurethral resection of bladder tumor (TURBT).

methodsFrom February 2010 to January 2014, a total of 41 patients older than 75 years, with T2-3 N0-1 high-grade MIBC, a Karnofsky index (KI) of at least 90% and/or a Barthel scale score of at least 95, were treated with TURBT followed by radiotherapy (RT) with or without chemotherapy, and were prospectively followed-up.

resultsThe mean age of patients was 82 years (range 76-88). Median follow-up was 47 months for surviving patients. Mean Charlson Comorbidity Index (CCI) score was 5 points. 28 patients (68.29%) were T2N0. All received 3D-CRT to a mean dose of 60 Gy (range 48.6-66 Gy), and chemotherapy was delivered to 34 patients (83%). Cause-specific survival (CSS) was 86 and 78.8% at 1 and 5 years, respectively. Patients achieving a complete response lived longer (48 vs 14 m, p = 0.036) than those with a progressive disease, who were more likely to die from cancer than from other causes (HR 3.865, IC95% 1.562-9.562). Dead patients had a longest treatment time (mean 56.78 vs 48.91 days, p = 0.019) than survivors.

conclusionRT with contemporary 3D-CRT techniques after TURBT for MIBC in elderly patients is feasible and well-tolerated. Achieving a maximal response and shortening the total radiation treatment time may improve outcomes and quality of life.

Indexed as

Quality of LifeAgedAged, 80 and overCohort StudiesFemaleFollow-Up StudiesHumansMaleMuscle NeoplasmsNeoplasm Recurrence, LocalOrgan Sparing TreatmentsPrognosisRadiotherapy, ConformalSurvival RateUrinary Bladder NeoplasmsBladder cancerElderlyRadiotherapyTrimodality

Identifiers

PMID29159793
OpenAlexW2770680225

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.